Literature DB >> 18047836

Severity dependent increases in circulating cardiac troponin I and MMP-9 concentrations after experimental acute pulmonary thromboembolism.

Juliana A Uzuelli1, Carlos A C Dias-Junior, Jose E Tanus-Santos.   

Abstract

BACKGROUND: Making the diagnosis of acute pulmonary thromboembolism (APT) and assessing its severity is very challenging. While cardiac troponin I (cTnI) concentrations are promising in risk stratification, no previous study has examined whether there is a linear relation between cTnI concentrations and the severity of APT. Moreover, matrix metalloproteinases (MMPs) are involved in the pathophysiology of APT. However, it is unknown whether the increases in MMP concentrations after APT reflect the severity of this condition. We examined whether the circulating concentrations of these biomarkers increase in proportion to the severity of experimental APT induced in anesthetized dogs.
METHODS: APT was induced with autologous blood clots (saline, 1, 3, or 5 ml/kg) injected into the right atrium. Hemodynamic evaluations were carried out for 120 min. Gelatin zymography of MMP-2 and MMP-9 from plasma samples were performed and serum cTnI concentrations were determined at baseline and 120 min after APT.
RESULTS: While no significant increases in pro-MMP-2 concentrations were found after APT, pro-MMP-9 concentrations increased by 80% only after 5 ml/kg of clot embolization. Serum cTnI and plasma pro-MMP-9 concentrations correlated positively with pulmonary vascular resistance (P=0.007 and rs=0.833 for troponin I, and P=0.034 and rs=0.684 for pro-MMP-9) and with pulmonary artery pressure (P=0.005 and rs=0.610 for troponin I, and P=0.022 and rs=0.720 for pro-MMP-9).
CONCLUSIONS: Circulating cTnI and pro-MMP-9 increase in proportion to the severity of APT, although the increases in plasma pro-MMP-9 are less clear with less severe APT. These findings may be relevant for clinical APT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18047836     DOI: 10.1016/j.cca.2007.11.001

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

1.  Targeting RV failure and cardiomyocyte injury in acute pulmonary thromboembolism.

Authors:  Jose E Tanus-Santos
Journal:  Nat Rev Cardiol       Date:  2013-08-20       Impact factor: 32.419

2.  Antioxidant treatment protects against matrix metalloproteinase activation and cardiomyocyte injury during acute pulmonary thromboembolism.

Authors:  Ozelia Sousa-Santos; Evandro M Neto-Neves; Karina C Ferraz; Carla S Ceron; Elen Rizzi; Raquel F Gerlach; Jose E Tanus-Santos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-05-03       Impact factor: 3.000

3.  Reappraisal of quantitative gel zymography for matrix metalloproteinases.

Authors:  Tommaso Prescimone; Danika Tognotti; Chiara Caselli; Manuela Cabiati; Andrea D'Amico; Silvia Del Ry; Daniela Giannessi
Journal:  J Clin Lab Anal       Date:  2014-03-19       Impact factor: 2.352

4.  Circulating Porphyromonas gingivalis lipopolysaccharide resets cardiac homeostasis in mice through a matrix metalloproteinase-9-dependent mechanism.

Authors:  Kristine Y Deleon-Pennell; Lisandra E de Castro Brás; Merry L Lindsey
Journal:  Physiol Rep       Date:  2013-10-02

5.  Effect of simvastatin on the SIRT2/NF-κB pathway in rats with acute pulmonary embolism.

Authors:  Zhi-Yao Wu; Hui Li; Yong-Jun Tang
Journal:  Pharm Biol       Date:  2018-12       Impact factor: 3.503

6.  Matrix metalloproteinase inhibition attenuates right ventricular dysfunction and improves responses to dobutamine during acute pulmonary thromboembolism.

Authors:  Evandro M Neto-Neves; Ozelia Sousa-Santos; Karina C Ferraz; Elen Rizzi; Carla S Ceron; Minna M D Romano; Luis G Gali; Benedito C Maciel; Richard Schulz; Raquel F Gerlach; Jose E Tanus-Santos
Journal:  J Cell Mol Med       Date:  2013-11-06       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.